Neeta Somaiah, MD, discusses the significance of the Peak study and what an approval of bezuclastinib plus sunitinib would mean for GIST.
|Articles|June 21, 2021
Treatment Strategies in HER2+ Gastrointestinal Malignancies
This article discusses case studies and treatment strategies in HER2-postive gastrointestinal malignancies, and features insights from experts John Marshall, MD, Yelena Y Janjigian, MD, Melissa Lumish, MD, Daniel Catenacci, MD, Carolina Soto Chervin, MD, PhD, Wells Messersmith, MD, Robert Lentz, MD, Zev Wainberg, MD, and Vina Pulido Nguyen, MD. Sponsored in part by Daiichi Sankyo. Content independently developed by OncLive.
Advertisement
Advertisement
Related to this article
Updated ASCO Living Guideline recommendations expand frontline therapy for HER2-positive gastroesophageal cancer to include zanidatamab-based regimens.
Paul E. Oberstein, MD, discusses autogene cevumeran, a personalized mRNA vaccine, which is being evaluated for pancreatic ductal adenocarcinoma.
Following the RASolute 302 readout, ESMO now endorses daraxonrasib after chemotherapy progression in RAS-mutated metastatic pancreatic cancer.
The top 5 OncLive TV videos of the week cover insights in multiple myeloma, melanoma, ovarian cancer, prostate cancer, and hepatocellular carcinoma.
The FDA approved iberdomide-based therapy for relapsed myeloma, rejected a neuroendocrine tumor therapy, and more.
The CLDN18.2/CD47 bispecific antibody spevatamig has received FDA fast track designation for advanced and metastatic biliary tract carcinoma.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Advertisement
Trending on OncLive
1
ASCO Guideline Update Broadens First-Line Treatment Options for HER2+ Gastroesophageal Cancer
2
CAR T-Cell Therapy Continues to Make Its Case in Early Relapsed Myeloma
3
ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma
4
FDA Awards Fast Track Designation to Safusidenib in IDH1-Mutant Glioma
5